What the correction actually says
The correction is a routine academic fix. It addresses a previous publication about Casdatifan, a drug targeting HIF-2α, and how that biology relates to durable responses in kidney cancer. No new data, no dramatic reversal. Just a factual amendment to a peer-reviewed study. That's it.
